Picture Berlin Partner Special Topic Well-trained Professionals 650x100px

Product › Details

adenosine receptor antagonist

	Next higher product group	cancer drug
	Status	2015-10-21 development p1 existent
	Organisation	Novartis AG (NYSE: NVS)
	Group	Novartis (Group)
	Organisation 2	Palobiofarma S.L.

Record changed: 2023-07-10

Picture EBD Group Biotech Showcase 2024 San Francisco 650x200px

More documents for adenosine receptor antagonist

[1] iTeos Therapeutics Inc.. (6/9/20). "Press Release: iTeos Therapeutics Strengthens Leadership Team. Matthew Gall Joins as Chief Financial Officer". Cambridge, MA & Gosselies....
[2] iTeos Therapeutics Inc.. (4/1/20). "Press Release: iTeos Therapeutics Closes $125 Million Series B2 Financing". Cambridge, MA & Gosselies....
[3] iTeos Therapeutics S.A.. (1/30/20). "Press Release: iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region". Gosselies & Cambridge, MA....
[4] iTeos Therapeutics S.A.. (12/12/19). "Press Release: iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with Keytruda". Gosselies & Cambridge, MA....
[5] iTeos Therapeutics S.A.. (8/13/19). "Press Release: iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer". Gosselies & Cambridge, MA....
[6] AstraZeneca plc. (3/14/19). "Press Release: AstraZeneca Showcases Next-generation Oncology Pipeline Addressing Unmet Patient Needs at AACR Annual Meeting"....
[7] AdoRx Therapeutics Ltd.. (2/28/19). "Press Release: AdoRx Therapeutics Announces Collaboration With Johnson & Johnson Innovation to Develop Novel Lung Cancer Therapeutics". Edinburgh....
[8] Taiho Ventures, LLC. (10/16/18). "Press Release: Taiho Ventures Expands Investment Pool to US$300 Million to Continue Quality Investments and Accelerate Open Innovation". Menlo Park, CA....
[9] iTeos Therapeutics S.A.. (7/3/18). "Press Release: iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer". Gosselies....
[10] iTeos Therapeutics S.A.. (6/27/18). "Press Release: iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director". Gosselies....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]